`
`Filed on behalf of: Par Pharmaceutical, Inc.
`
`
`
`
`
`UNITED STATES PATENT AND TRADEMARK OFFICE
`_______________________
`
`BEFORE THE PATENT TRIAL AND APPEAL BOARD
`_______________________
`
`PAR PHARMACEUTICAL, INC.
`Petitioner
`
`v.
`
`NOVARTIS AG.
`Patent Owner
`_______________________
`
`Case IPR2016-01059
`U.S. Patent No. 5,665,772
`_______________________
`
`Before PATRICK E. BAKER, Trial Paralegal.
`
`
`PETITIONER’S UPDATED MANDATORY NOTICES
`
`
`
`
`
`
`
`IPR2016-01059
`U.S. Patent No. 5,665,772
`
`
`Pursuant
`
`to 37 C.F.R. § 42.8, Petitioner Par Pharmaceutical, Inc.
`
`(“Petitioner”) hereby submits the following Updated Mandatory Notices.
`
`1.
`
`Real Parties-In-Interest (§ 42.8(b)(1)) (UNCHANGED)
`
`Petitioner Par Pharmaceutical, Inc. (“Par”) is a real-party-in-interest for this
`
`proceeding. Out of an abundance of caution, and as a result of ongoing integration
`
`and reorganization activities, Petitioner identifies the following additional entities
`
`as real-parties-in-interest who, going forward, may have control over this
`
`proceeding: Endo International PLC; Endo DAC; Endo Management Limited;
`
`Endo Luxembourg Holding Company S.a.r.l.; Endo Luxembourg Finance
`
`Company I S.a.r.l.; Endo U.S. Inc.; Endo US Holdings Luxembourg I S.a.r.l.; Endo
`
`US Holdings Luxembourg II S.a.r.l.; Endo Health Solutions Inc.; Hawk
`
`Acquisition Ireland Limited; and Par Pharmaceutical Companies, Inc.1 No other
`
`
`1 As a result of Endo International PLC’s acquisition of Par Pharmaceutical, Inc.,
`
`Petitioner states that: Sky Growth Intermediate Holdings Corporation I, Sky
`
`Growth Intermediate Holdings Corporation II and Par Pharmaceutical Companies,
`
`Inc. were merged into and reorganized with Par Pharmaceutical Holdings, Inc.,
`
`which was immediately thereafter re-named Par Pharmaceutical Companies, Inc.
`
`For clarity, the newly reorganized Par Pharmaceutical Companies, Inc. is not iden-
`
`tical to the entity previously known by the same name.
`
`1
`
`
`
`IPR2016-01059
`U.S. Patent No. 5,665,772
`
`parties exercised or could have exercised control over this petition; no other parties
`
`funded or directed this petition. See Office Patent Trial Practice Guide, 77 Fed.
`
`Reg. 48759-60.
`
`2.
`
`Related Matters (§ 42.8(b)(2)) (UNCHANGED)
`
`Novartis Pharm. Corp. et al. v. Par Pharm., Inc., No. 1:14-cv-1289-RGA
`
`(D. Del.). Novartis Pharm. Corp. et al. v. Par Pharm., Inc., No. 1:14-cv-1494-
`
`RGA (D. Del.). Novartis Pharm. Corp. et al. v. Par Pharm., Inc., No. 1:15-cv-78-
`
`RGA (D. Del.). Novartis Pharm. Corp. et al. v. Par Pharm., Inc., No. 1:15-cv-
`
`475-RGA (D. Del.). Novartis Pharm. Corp. et al. v. Par Pharm., Inc., No. 1:15-
`
`cv-1050-RGA (D. Del.). Petition for Inter Partes Review of U.S. Patent No.
`
`5,665,772, No. IPR2016-00084. According to USPTO records, no patent claims
`
`priority to the ’772 Patent.
`
`3.
`
`Lead and Back-Up Counsel (§ 42.8(b)(3)) (UPDATED)
`
`Lead Counsel
`
`Back-Up Counsel
`
`Daniel G. Brown (Reg. No. 54,005)
`daniel.brown@lw.com
`Postal & Hand-Delivery Address:
`Latham & Watkins LLP
`885 Third Avenue
`New York, NY 10022-4834
`T: 212.906.1200; F: 212.751.4864
`Back-Up Counsel
`
`Robert Steinberg (Reg. No. 33,144)
`bob.steinberg@lw.com
`Postal & Hand-Delivery Address:
`Latham & Watkins LLP
`355 South Grand Avenue
`Los Angeles, CA 90071-1560
`T: 213.485.1234; F: 213.891.8763
`
`
`2
`
`
`
`IPR2016-01059
`U.S. Patent No. 5,665,772
`
`
`Jonathan M. Strang (Reg. No. 61,724)
`jonathan.strang@lw.com
`Postal & Hand-Delivery Address:
`Latham & Watkins LLP
`555 Eleventh Street, NW, Ste. 1000
`Washington, DC 20004-1304
`T: 202.637.2200; F: 202.637.2201
`
`
`4.
`
`Service Information (§ 42.8(b)(4)) (UPDATED)
`
`Lead Counsel
`
`Back-Up Counsel
`
`Daniel G. Brown (Reg. No. 54,005)
`daniel.brown@lw.com
`Postal & Hand-Delivery Address:
`Latham & Watkins LLP
`885 Third Avenue
`New York, NY 10022-4834
`T: 212.906.1200; F: 212.751.4864
`Back-Up Counsel
`
`Jonathan M. Strang (Reg. No. 61,724)
`jonathan.strang@lw.com
`Postal & Hand-Delivery Address:
`Latham & Watkins LLP
`555 Eleventh Street, NW, Ste. 1000
`Washington, DC 20004-1304
`T: 202.637.2200; F: 202.637.2201
`
`
`
`Dated: May 24, 2016
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`Robert Steinberg (Reg. No. 33,144)
`bob.steinberg@lw.com
`Postal & Hand-Delivery Address:
`Latham & Watkins LLP
`355 South Grand Avenue
`Los Angeles, CA 90071-1560
`T: 213.485.1234; F: 213.891.8763
`
`
`By: /Daniel G. Brown/
`
`Daniel G. Brown (Reg. No. 54,005)
`Latham & Watkins LLP
`885 Third Avenue
`New York, NY 10022-4834
`212.906.1200; 212.751.4864 (Fax)
`
`Counsel for Petitioner
`
`3
`
`
`
`IPR2016-01059
`U.S. Patent No. 5,665,772
`
`
`CERTIFICATE OF SERVICE
`
`Pursuant to 37 C.F.R. § 42.6(e), I certify that on this 24th day of May, 2016,
`
`
`
`a true and correct copy of the foregoing Petitioner’s Updated Mandatory Notices
`
`was served by Federal Express overnight delivery on Patent Owner’s counsel:
`
`Novartis Pharmaceutical Corporation
`Intellectual Property Department
`One Health Plaza 433/2
`East Hanover, NJ 07936-1080
`
`Nicholas N. Kallas (Reg. No. 31,530)
`Raymond R. Mandra (Reg. No. 34,382)
`Fitzpatrick, Cella, Harper & Scinto
`1290 Avenue of the Americas
`New York, NY 10104-3800
`ZortressAfinitorIPR@fchs.com
`
`via FEDERAL EXPRESS overnight delivery, on May 24, 2016
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`By: /Daniel G. Brown/
`
`Daniel G. Brown (Reg. No. 54,005)
`Latham & Watkins LLP
`885 Third Avenue
`New York, NY 10022-4834
`212.906.1200; 212.751.4864 (Fax)
`
`Counsel for Petitioner